BioCorRx is a small, early-stage addiction treatment company with two core activities: licensing treatment programs to healthcare providers, and developing a proprietary pharmaceutical implant. Its Beat Addiction Recovery Program combines CBT modules with peer support via a mobile app, and BioCorRx licenses this program to third-party treatment centers rather than operating centers itself. On the pharmaceutical side, BioCorRx — through its majority-owned subsidiary BioCorRx Pharmaceuticals — is developing BICX104, a biodegradable, long-acting implantable naltrexone pellet for opioid use disorder and methamphetamine use disorder. BICX104 is still in clinical trials and has not received FDA approval. In March 2025, BioCorRx acquired Lucemyra, an FDA-approved non-opioid medication for opioid withdrawal symptoms, which represents the company's first commercially approved pharmaceutical product. BioCorRx also runs a smaller weight loss program, UnCraveRx, which pairs weight loss drugs with wellness coaching. Revenue today comes from a mix of NIH grant funding supporting BICX104 research, Lucemyra product sales, program licensing fees, and management services provided to an affiliated medical practice. The company's long-term commercial prospects depend heavily on BICX104 gaining FDA approval, which would give BioCorRx a novel long-duration naltrexone delivery option targeting patient compliance as a key differentiator.